MA30061B1 - Preparation solide - Google Patents
Preparation solideInfo
- Publication number
- MA30061B1 MA30061B1 MA31045A MA31045A MA30061B1 MA 30061 B1 MA30061 B1 MA 30061B1 MA 31045 A MA31045 A MA 31045A MA 31045 A MA31045 A MA 31045A MA 30061 B1 MA30061 B1 MA 30061B1
- Authority
- MA
- Morocco
- Prior art keywords
- insulin sensitizer
- solid preparation
- active component
- coated
- sensitizer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention vise à fournir une préparation solide qui contient un sensibilisateur à l'insuline et un composant actif autre qu'un sensibilisateur à l'insuline et manifeste une conduite de dissolution d'un sensibilisateur à l'insuline semblable à celle d'un sensibilisateur à l'insuline provenant d' "une préparation solide contenant seulement un sensibilisateur à l'insuline à titre de composant actif". La préparation solide comprend "une partie contenant des particules enrobées dans laquelle les particules contenant un sensibilisateur à l'insuline sont enrobées avec du lactose ou un alcool de sucre" et "une partie contenant un composant actif autre qu'un sensibilisateur à l'insuline".
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005370375 | 2005-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30061B1 true MA30061B1 (fr) | 2008-12-01 |
Family
ID=37951491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31045A MA30061B1 (fr) | 2005-12-22 | 2008-06-18 | Preparation solide |
Country Status (24)
Country | Link |
---|---|
US (1) | US8071130B2 (fr) |
EP (1) | EP1962811B1 (fr) |
JP (1) | JP5179363B2 (fr) |
KR (1) | KR20080080126A (fr) |
CN (1) | CN101384251B (fr) |
AR (1) | AR058605A1 (fr) |
AU (1) | AU2006328328B2 (fr) |
BR (1) | BRPI0620020A2 (fr) |
CA (1) | CA2633149C (fr) |
CR (1) | CR10032A (fr) |
ES (1) | ES2576258T3 (fr) |
GE (1) | GEP20115245B (fr) |
HR (1) | HRP20160679T1 (fr) |
IL (1) | IL191774A0 (fr) |
MA (1) | MA30061B1 (fr) |
MY (1) | MY149306A (fr) |
NO (1) | NO20083104L (fr) |
NZ (1) | NZ569071A (fr) |
PE (1) | PE20110019A1 (fr) |
RU (1) | RU2426530C2 (fr) |
TW (1) | TWI384985B (fr) |
UA (1) | UA91729C2 (fr) |
WO (1) | WO2007072992A2 (fr) |
ZA (1) | ZA200805147B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2019669B1 (fr) | 2006-05-23 | 2011-11-23 | Takeda Pharmaceutical Company Limited | Préparation orale comprenant de la pioglitazone |
BRPI0807453B8 (pt) | 2007-02-01 | 2021-05-25 | Takeda Pharmaceuticals Co | preparação sólida |
WO2009028487A1 (fr) * | 2007-08-27 | 2009-03-05 | Asahi Kasei Chemicals Corporation | Procédé de fabrication de comprimés contenant à la fois de cellulose cristalline et des granulés |
NZ594738A (en) * | 2009-01-23 | 2013-11-29 | Hanmi Science Co Ltd | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
MX337603B (es) * | 2009-11-30 | 2016-03-10 | Adare Pharmaceuticals Inc | Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion. |
CN101804056A (zh) * | 2010-04-16 | 2010-08-18 | 山东新华制药股份有限公司 | 盐酸吡格列酮、格列美脲的复方片剂及制备方法 |
EP2611434A1 (fr) | 2010-09-01 | 2013-07-10 | Lupin Limited | Composition pharmaceutique contenant de la metformine et de la pioglitazone |
EP2618827B1 (fr) * | 2010-09-21 | 2021-06-02 | Intekrin Therapeutics, Inc. | Compositions pharmaceutiques solides antidiabétiques |
FR2966828B1 (fr) * | 2010-11-02 | 2012-12-28 | Roquette Freres | Poudre de polysaccharide et de polyol, comprimable et de haute viscosite |
WO2013034174A1 (fr) | 2011-09-06 | 2013-03-14 | ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. | Préparations solides de pioglitazone et de glimépiride |
EP2753309B1 (fr) * | 2011-09-08 | 2020-01-01 | Hexal AG | Composition pharmaceutique pour l'administration orale dotée d' une statine |
BR112014008744A2 (pt) | 2011-10-21 | 2017-04-18 | Takeda Pharmaceuticals Co | preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
CN102641280A (zh) * | 2012-04-23 | 2012-08-22 | 重庆康刻尔制药有限公司 | 一种盐酸吡格列酮格列美脲组合药物、片剂及其应用 |
CA2979033A1 (fr) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie |
US20160331689A1 (en) * | 2015-05-12 | 2016-11-17 | SE Tylose USA, Inc. | Aqueous enteric coating composition |
KR101782119B1 (ko) * | 2016-02-01 | 2017-10-23 | 주식회사 한독 | 테넬리글립틴 및 설포닐우레아계 약물을 포함하는 정제 |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
CN111410687B (zh) * | 2020-02-21 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3152978B2 (ja) | 1991-12-17 | 2001-04-03 | 塩野義製薬株式会社 | 二層錠およびその製造方法 |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5859037A (en) | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
AP1600A (en) | 1997-06-18 | 2006-04-28 | Smithkline Beecham Plc | Combination of a thiazolidinedione and a sulphonylurea for treating diabetes |
GB9715306D0 (en) | 1997-07-18 | 1997-09-24 | Smithkline Beecham Plc | Novel method of treatment |
US7399485B1 (en) | 1998-07-28 | 2008-07-15 | Takeda Pharmaceutical Company Limited | Rapidly Disintegrable solid preparation |
BR9915285A (pt) * | 1998-11-12 | 2001-08-07 | Smithkline Beecham Plc | Composição farmacêutica para liberação modificada de um sensitivador de insulina e um outro agente antidiabético |
EP1140145B2 (fr) | 1999-01-14 | 2019-05-15 | Amylin Pharmaceuticals, LLC | Nouvelles formulations d'agonistes de l'exendine et modes d'administration |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
AU2001294192A1 (en) * | 2000-10-06 | 2002-04-22 | Takeda Chemical Industries Ltd. | Solid preparations |
JP4284017B2 (ja) * | 2000-10-06 | 2009-06-24 | 武田薬品工業株式会社 | 固形製剤 |
RU2177318C1 (ru) | 2000-12-21 | 2001-12-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция с антидиабетическим действием и способ ее получения |
US20040147584A2 (en) * | 2001-12-05 | 2004-07-29 | Aventis Pharma S.A. | 1,3-diarylprop-2-en-1-ones, compositions containing them and use thereof |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
EP1552832A1 (fr) | 2002-07-11 | 2005-07-13 | Takeda Pharmaceutical Company Limited | Procede de production d'une preparation recouverte |
ES2277142T3 (es) | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | Compuesto de dibencilamina y su uso medicinal. |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
NZ541749A (en) | 2003-01-29 | 2009-06-26 | Takeda Pharmaceutical | Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material |
US20040147564A1 (en) | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
WO2004069229A1 (fr) * | 2003-02-05 | 2004-08-19 | Ipca Laboratories Limited | Medicaments antidiabetiques a double liberation et procede de production de ceux-ci |
WO2004091587A1 (fr) * | 2003-04-17 | 2004-10-28 | Ipca Laboratories Limited | Liberation multiple de medicaments anti-diabete et procede de production associe |
MXPA05013147A (es) | 2003-06-06 | 2006-03-17 | Takeda Pharmaceutical | Preparacion solida. |
BRPI0412009A (pt) | 2003-06-27 | 2006-08-15 | Reddy Research Foundation | composições compreendendo balaglitazona e outros compostos antidiabéticos |
WO2005009407A2 (fr) * | 2003-07-29 | 2005-02-03 | Ranbaxy Laboratories Limited | Formulations pharmaceutiques d'olanzapine administrees par voie orale |
HUE028576T2 (en) * | 2003-10-31 | 2016-12-28 | Takeda Pharmaceuticals Co | Solid preparation containing pioglitazone, glimepiride and polyoxyethylene sorbitan fatty acid ester |
JP4361461B2 (ja) * | 2003-10-31 | 2009-11-11 | 武田薬品工業株式会社 | 固形製剤 |
US8263121B2 (en) | 2004-04-14 | 2012-09-11 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
WO2005102290A1 (fr) * | 2004-04-22 | 2005-11-03 | Ranbaxy Laboratories Limited | Compositions pharmaceutiques formees d'un biguanide et d'une sulfonyluree |
-
2006
- 2006-12-21 TW TW095148113A patent/TWI384985B/zh not_active IP Right Cessation
- 2006-12-21 UA UAA200808310A patent/UA91729C2/ru unknown
- 2006-12-21 AR ARP060105709A patent/AR058605A1/es not_active Application Discontinuation
- 2006-12-21 ZA ZA200805147A patent/ZA200805147B/xx unknown
- 2006-12-21 JP JP2008528691A patent/JP5179363B2/ja active Active
- 2006-12-21 WO PCT/JP2006/326169 patent/WO2007072992A2/fr active Application Filing
- 2006-12-21 CN CN200680053318.XA patent/CN101384251B/zh active Active
- 2006-12-21 KR KR1020087014632A patent/KR20080080126A/ko active IP Right Grant
- 2006-12-21 AU AU2006328328A patent/AU2006328328B2/en not_active Ceased
- 2006-12-21 EP EP06843549.4A patent/EP1962811B1/fr active Active
- 2006-12-21 US US12/086,700 patent/US8071130B2/en active Active
- 2006-12-21 GE GEAP200610776A patent/GEP20115245B/en unknown
- 2006-12-21 PE PE2010001114A patent/PE20110019A1/es not_active Application Discontinuation
- 2006-12-21 NZ NZ569071A patent/NZ569071A/en not_active IP Right Cessation
- 2006-12-21 ES ES06843549.4T patent/ES2576258T3/es active Active
- 2006-12-21 CA CA2633149A patent/CA2633149C/fr active Active
- 2006-12-21 MY MYPI20082251A patent/MY149306A/en unknown
- 2006-12-21 RU RU2008130074/15A patent/RU2426530C2/ru not_active IP Right Cessation
- 2006-12-21 BR BRPI0620020-6A patent/BRPI0620020A2/pt not_active IP Right Cessation
-
2008
- 2008-05-27 IL IL191774A patent/IL191774A0/en unknown
- 2008-05-30 CR CR10032A patent/CR10032A/es not_active Application Discontinuation
- 2008-06-18 MA MA31045A patent/MA30061B1/fr unknown
- 2008-07-10 NO NO20083104A patent/NO20083104L/no not_active Application Discontinuation
-
2016
- 2016-06-14 HR HRP20160679TT patent/HRP20160679T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2633149A1 (fr) | 2007-06-28 |
IL191774A0 (en) | 2008-12-29 |
US20090028939A1 (en) | 2009-01-29 |
ZA200805147B (en) | 2010-05-26 |
KR20080080126A (ko) | 2008-09-02 |
WO2007072992A2 (fr) | 2007-06-28 |
CN101384251A (zh) | 2009-03-11 |
MY149306A (en) | 2013-08-30 |
ES2576258T3 (es) | 2016-07-06 |
AR058605A1 (es) | 2008-02-13 |
HRP20160679T1 (hr) | 2016-07-15 |
BRPI0620020A2 (pt) | 2011-10-25 |
EP1962811B1 (fr) | 2016-04-27 |
CA2633149C (fr) | 2015-06-30 |
EP1962811A2 (fr) | 2008-09-03 |
JP5179363B2 (ja) | 2013-04-10 |
NZ569071A (en) | 2011-01-28 |
TW200731971A (en) | 2007-09-01 |
JP2009520681A (ja) | 2009-05-28 |
GEP20115245B (en) | 2011-06-27 |
CN101384251B (zh) | 2014-09-03 |
WO2007072992A3 (fr) | 2007-12-06 |
UA91729C2 (ru) | 2010-08-25 |
US8071130B2 (en) | 2011-12-06 |
RU2008130074A (ru) | 2010-01-27 |
PE20110019A1 (es) | 2011-01-27 |
CR10032A (es) | 2008-10-03 |
TWI384985B (zh) | 2013-02-11 |
AU2006328328B2 (en) | 2012-08-30 |
NO20083104L (no) | 2008-09-19 |
AU2006328328A1 (en) | 2007-06-28 |
RU2426530C2 (ru) | 2011-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30061B1 (fr) | Preparation solide | |
TN2010000073A1 (fr) | Compositon pharmaceutique contenant un derive de benzene substitue par glucopyranosyle | |
Woolbright et al. | Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice | |
MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
MA47399B1 (fr) | Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 | |
MA44206B1 (fr) | Comprimé orodispersible comprenant estetrol | |
MA30990B1 (fr) | Antagonistes du recepteur de progesterone. | |
MA30504B1 (fr) | Compositions pharmaceutiques stabilisees comprenant de la fesoterodine | |
MA32548B1 (fr) | Composition pharmaceutique a base de progesterone micronisee et ses utilisations | |
MA31862B1 (fr) | Anticorps anti-mésothéline et leurs utilisations | |
Roque Bravo et al. | Cocaine: an updated overview on chemistry, detection, biokinetics, and pharmacotoxicological aspects including abuse pattern | |
MA29836B1 (fr) | Proteines de fusion avec l'albumine | |
TN2009000138A1 (fr) | Biaryl-ether-urees | |
MA33057B1 (fr) | Composition pharmaceutique solide comprenant de l'amlodipine et du losartan | |
MA31169B1 (fr) | Preparation solide comprenant de l'alogliptine et de la pioglitazone | |
Goel et al. | Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: protection by angiotensin converting enzyme inhibition | |
MA30085B1 (fr) | Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione | |
MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
MA31471B1 (fr) | Formulations d'anticorps | |
MA27835A1 (fr) | Methodes pour le traitement de l'atherosclerose, des dyslipemies et conditions apparentees et compositions pharmaceutiques | |
MA30470B1 (fr) | Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste. | |
MA27729A1 (fr) | Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre | |
MA29273B1 (fr) | Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur | |
TNSN00139A1 (fr) | Acides phenoxyacetiques substitues | |
MA31796B1 (fr) | Composes organiques |